阿瑞匹坦联合地塞米松及多拉司琼治疗肺小细胞癌EP方案化疗致恶心呕吐的效果  

Efficacy of Aripitan combined with Dexamethasone and Dorasetron in the treatment of nausea and vomiting caused by EP regimen chemotherapy for small cell lung cancer

作　　者：高健 徐细明[1] 陈嘉羽[1] GAO Jian;XU Ximing;CHEN Jiayu(Cancer Center,Renmin Hospital of Wuhan University,Hubei Province,Wuhan430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,湖北武汉430060

出　　处：《中国医药导报》2021年第5期88-92,108,共6页China Medical Herald

基　　金：国家自然科学基金资助项目(31971166)。

摘　　要：目的评价阿瑞匹坦联合地塞米松及多拉司琼治疗小细胞肺癌EP方案化疗致恶心呕吐的效果。方法回顾性分析2017年12月—2019年12月武汉大学人民医院肿瘤中心40例初治且明确病理诊断的小细胞肺癌患者临床资料,依据随机数字表法将其分为对照组及实验组,每组各20例。所有患者均给予依托泊苷及顺铂联合化疗,对照组每天化疗前30 min给予多拉司琼静脉滴注及口服地塞米松预防性止吐治疗,实验组每天化疗前30 min给予多拉司琼静脉滴注、口服地塞米松及阿瑞吡坦预防性止吐治疗。比较两组化疗后急性期、迟发期和整体期恶心呕吐控制情况及不良反应。结果两组急性期、延迟期及整体期恶心控制总有效率比较,差异无统计学意义(P>0.05)。两组急性期、整体期呕吐控制总有效率比较,差异无统计学意义(P>0.05);实验组延迟期呕吐控制总有效率高于对照组,差异有统计学意义(P<0.05)。两组常见不良反应均为Ⅰ~Ⅱ级,无Ⅲ~Ⅳ级不良反应。结论阿瑞匹坦联合地塞米松及多拉司琼治疗小细胞肺癌EP方案所致恶心呕吐的效果良好,且不良反应小,尤其对延迟期呕吐疗效确切。Objective To evaluate the efficacy of Aripitant combined with Dexamethasone and Dolasetron in the treatment of nausea and vomiting caused by EP regimen chemotherapy for small cell lung cancer.Methods Clinical data of 40 small cell lung cancer patients with initial treatment and definite pathological diagnosis from December 2017 to December 2019 in Cancer Center of Renmin Hospital of Wuhan University were retrospectively analyzed.All patients were divided into control group and experimental group according to random number table method,20 cases in each group.All patients were given Etoposide and Cisplatin combined chemotherapy,control group was given preventive antiemetic therapy of intravenous drip of Dorasetron and oral Dexamethasone 30 minutes before chemotherapy,experimental group was given preventive antiemetic therapy of intravenous infusion of Dorasetron,oral Dexamethasone and Aripiptan 30 minutes before chemotherapy.Control of nausea and vomiting induced by chemotherapy in acute,delayed and whole stage and adverse reactions were compared between two groups.Results There were no significant differences in total effective rate of nausea control in acute phase,delayed phase and overall phase between two groups(P>0.05).There was no significant difference in total effective rate of vomiting control in acute phase and overall phase between two groups(P>0.05).Total effective rate of vomiting control in experimental group was higher than that in control group,and the difference was statistically significant(P<0.05).The common adverse reactions of two groups were gradeⅠ-Ⅱ,and there were no gradeⅢ-Ⅳadverse reactions.Conclusion Aripitan combined with Dexamethasone and Dorasetron has a good effect in the treatment of nausea and vomiting caused by EP regimen for small cell lung cancer,and the adverse reactions are small,especially it is effective for delayed vomiting.

关 键 词：神经激肽1-受体拮抗剂 阿瑞匹坦 小细胞肺癌 化疗 预防性止吐 

分 类 号：R734.2[医药卫生—肿瘤]